(Albany, United States) As per DelveInsight’s assessment, globally, the Geographic Atrophy pipeline constitutes 23+ key companies continuously working towards developing 25+ Geographic Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Geographic Atrophy pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Geographic Atrophy NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Geographic Atrophy Pipeline treatment landscape of the report, click here @ Geographic Atrophy Pipeline Outlook
Key Takeaways from the Geographic Atrophy Pipeline Report
- DelveInsight’s Geographic Atrophy Pipeline analysis depicts a robust space with 23+ active players working to develop 25+ pipeline treatment therapies.
- The leading companies are working in the Geographic Atrophy Market include Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc, Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others.
- Promising Geographic Atrophy Pipeline Therapies in the various stages of development include ACU-4429, Tinlarebant, ANX007, PEGCETACOPLAN (APL-2), Danicopan, CLG561, LFG316, Sham Injection, Pegcetacoplan, and others.
- On July 2023, Genentech Inc. announced a study of phase 2 clinical trials for OpRegen. This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.
- On July 2023, Belite Bio Inc announced a study of phase 3 clinical trials for Tinlarebant. This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Geographic Atrophy Overview
Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris.
For further information, refer to the detailed Geographic Atrophy Unmet Needs, click here for Geographic Atrophy Ongoing Clinical Trial Analysis
Geographic Atrophy Emerging Drugs Profile
- IONIS-FB-LRx: Ionis Pharmaceuticals
IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye.
- Zimura: IVERIC bio
Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related macular degeneration.
Geographic Atrophy Pipeline Therapeutics Assessment
There are approx. 23+ key companies which are developing the therapies for Geographic Atrophy. The Geographic Atrophy companies which have their Geographic Atrophy drug candidates in the most advanced stage, i.e. phase III include, IVERIC bio.
Request a sample and discover the recent advances in Geographic Atrophy Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Geographic Atrophy Segmentation
Geographic Atrophy Drugs and Companies
- ACU-4429: Kubota Vision Inc.
- Tinlarebant: Belite Bio Inc.
- ANX007: Annexon Inc.
Geographic Atrophy Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Geographic Atrophy Therapeutics Market include-
Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc, Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others.
Dive deep into rich insights for drugs for Geographic Atrophy Pipeline, click here for Geographic Atrophy Unmet Needs and Analyst Views
Scope of the Geographic Atrophy Pipeline Report
- Coverage- Global
- Companies- Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc, Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others.
- Therapies- ACU-4429, Tinlarebant, ANX007, PEGCETACOPLAN (APL-2), Danicopan, CLG561, LFG316, Sham Injection, Pegcetacoplan, and others.
- Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Geographic Atrophy Merger and acquisitions, Licensing Activities
Table of Content
- Introduction
- Executive Summary
- Geographic Atrophy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Geographic Atrophy – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Zimura: IVERIC bio
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IONIS-FB-LRx: Ionis Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Geographic Atrophy Key Companies
- Geographic Atrophy Key Products
- Geographic Atrophy- Unmet Needs
- Geographic Atrophy- Market Drivers and Barriers
- Geographic Atrophy- Future Perspectives and Conclusion
- Geographic Atrophy Analyst Views
- Geographic Atrophy Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services